Trial Condition(s):

Atrial Fibrillation

BAY59-7939, Japanese phase II in Atrial FibrillationTrial Status

Bayer Identifier:

11390

ClinicalTrials.gov Identifier:

NCT00779064

EudraCT Number:

Not Available

Study Completed

Trial Purpose

This is a clinical study investigating pharmacokinetics, pharmacodynamic effects and safety of BAY 59-7939 in patients with atrial fibrillation (originally described in Japanese).

Inclusion Criteria
- 20 years or older  
 - Japanese male or  female  
 - Non- valvular atrial fibrillation documented by     ECG  
 - Patients aged  60 years and older or with a risk   of stroke
Exclusion Criteria
- Prior stroke and TIA   
 - Patients in whom anticoagulants are  contraindicated

Trial Summary

Enrollment Goal
36
Trial Dates
black-arrow
Phase
2
Could I receive a placebo?
No
Products
Xarelto (Rivaroxaban, BAY59-7939)
Accepts Healthy Volunteers
No

Where to Participate

Loading...
Locations
Status
LocationsStatus
Locations

Investigative Site

Osaka, Japan, 540-0006

Status
Completed
 
Locations

Investigative Site

Osaka, Japan, 558-8558

Status
Completed
 
Locations

Investigative Site

Kitakyushu, Japan, 800-0057

Status
Completed
 
Locations

Investigative Site

Onga, Japan, 807-0051

Status
Completed
 
Locations

Investigative Site

Kurume, Japan, 830-8577

Status
Completed
 
Locations

Investigative Site

Kitahiroshima, Japan, 061-1134

Status
Completed
 
Locations

Investigative Site

Suita, Japan, 565-0871

Status
Completed
 
Locations

Investigative Site

Amagasaki, Japan, 660-8511

Status
Completed
 
Locations

Investigative Site

Osaka, Japan, 553-0003

Status
Completed
 
Locations

Investigative Site

Fukuoka, Japan, 811-0213

Status
Completed
 
Locations

Investigative Site

Fukuoka, Japan, 814-0180

Status
Completed
 

Trial Design